Current	O
prospects	O
for	O
controlling	O
cancer	B-Cancer
growth	O
with	O
non	O
-	O
cytotoxic	O
agents	O
-	O
-	O
nutrients	O
,	O
phytochemicals	O
,	O
herbal	O
extracts	B-Organism_substance
,	O
and	O
available	O
drugs	O
.	O

In	O
animal	O
or	O
cell	B-Cell
culture	I-Cell
studies	O
,	O
the	O
growth	O
and	O
spread	O
of	O
cancer	B-Cancer
can	O
be	O
slowed	O
by	O
many	O
nutrients	O
,	O
food	O
factors	O
,	O
herbal	O
extracts	B-Organism_substance
,	O
and	O
well	O
-	O
tolerated	O
,	O
available	O
drugs	O
that	O
are	O
still	O
rarely	O
used	O
in	O
the	O
clinical	O
management	O
of	O
cancer	B-Cancer
,	O
in	O
part	O
because	O
they	O
seem	O
unlikely	O
to	O
constitute	O
definitive	O
therapies	O
in	O
themselves	O
.	O

However	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
mechanistically	O
complementary	O
combinations	O
of	O
these	O
measures	O
could	O
have	O
a	O
worthwhile	O
impact	O
on	O
survival	O
times	O
and	O
,	O
when	O
used	O
as	O
adjuvants	O
,	O
could	O
improve	O
the	O
cure	O
rates	O
achievable	O
with	O
standard	O
therapies	O
.	O

The	O
therapeutic	O
options	O
available	O
in	O
this	O
regard	O
include	O
measures	O
that	O
:	O
down	O
-	O
regulate	O
serum	B-Organism_substance
free	O
IGF	O
-	O
I	O
;	O
suppress	O
the	O
synthesis	O
of	O
mevalonic	O
acid	O
and	O
/	O
or	O
certain	O
derivatives	O
thereof	O
;	O
modulate	O
arachidonate	O
metabolism	O
by	O
inhibiting	O
5	O
-	O
lipoxygenase	O
,	O
12	O
-	O
lipoxygenase	O
,	O
or	O
COX	O
-	O
2	O
;	O
antagonize	O
the	O
activation	O
of	O
AP	O
-	O
1	O
transcription	O
factors	O
;	O
promote	O
the	O
activation	O
of	O
PPAR	O
-	O
gamma	O
transcription	O
factors	O
;	O
and	O
that	O
suppress	O
angiogenesis	O
by	O
additional	O
mechanisms	O
.	O

Many	O
of	O
these	O
measures	O
appear	O
suitable	O
for	O
use	O
in	O
cancer	B-Cancer
prevention	O
.	O

